Posters

      GladiaTOX: global assessment of dose-response indicators in toxicology

      Belcastro, V.; Cano, S.; Marescotti, D.; Acali, S.; Gonzalez-Suarez, I.; Martin, F.; Bonjour, F.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.
      Conference date
      Mar 12, 2019
      Conference name

      Society of Toxicology (SOT) 2019
      Link to more information
      Topic
      Summary

      Drug discovery has historically relied on the massive screening of compound libraries with in vitro cell-based target assays. The challenges of performing larger screening campaigns while keeping time and costs limited has led the pharmaceutical industry to develop in vitro high-content screening (HCS) technologies. These techniques, generating thousands of data points per day, require standardized and robust data analysis procedures that can enable a rapid decision-making process. Quality control (QC), processing, and reporting are the typical steps applied to experimental HCS data. During QC sessions, all images’ control parameters are inspected against standard acceptance criteria. Processing includes data normalization, dose-response fitting, and evaluation of standard parameters, such as EC50 and minimal effective concentration (MEC). Analysis results are then shared via formatted reports. Deficient analysis pipelines lead to long, untraceable procedures. GladiaTOX is an open-source solution for HCS data processing and reporting that expands the tcpl package (toxcast pipeline, Filer et al. 2016). In addition to tcpl’s functionalities (multiple dose-response fitting and best fit selection), GladiaTOX (i) fetches raw image quantifications via a webservice layer, also allowing multiple (proprietary) systems to be integrated easily; (ii) computes MEC based also on historical data; (iii) exports results formatted for ToxPI GUI; (iv) aggregates single endpoint MECs into severity scores; and (v) implements a suite of functionalities for QC reporting to a structured PDF format. The effects of seven chemical constituents present in tobacco or tobacco smoke on normal human bronchial cells are reported as use case: three metals (arsenite, mercury, and selenite), two phenols (phenol and p-cresol), acrylamide, and naphthalene. Overall, metals show low MEC values (high toxicity) on most endpoints tested (including cytotoxicity assays, DNA damage, and oxidative stress). The severity scores rank metals as more toxic than phenols and assign low severity to acrylamide and naphthalene. GladiaTOX represents an all-in-one, open-source, flexible solution to store, process, and report HCS data in biomedical research.

      Related Publications

      Quantitative Adverse Outcome Pathway: A New Prediction Tool to Assess Human Risk of Decreased Lung Function When Switching from Combustible Cigarettes to Heated Tobacco Products

      Systems Toxicology

      An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

      Systems Toxicology

      Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses

      Systems Toxicology

      Quantitative Modeling of In Vitro Data Using an Adverse Outcome Pathway for the Risk Assessment of Decreased Lung Function in Humans

      Systems Toxicology

      Systems toxicology: The future of risk assessment

      Systems Toxicology

      Systems biology: Methods and applications

      Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.